Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Platelet Activation in Chronic Inflammatory Skin Diseases

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2012 by Meir Medical Center.
Recruitment status was:  Not yet recruiting
Sponsor:
Information provided by (Responsible Party):
Meir Medical Center
ClinicalTrials.gov Identifier:
NCT01759693
First received: December 28, 2012
Last updated: January 2, 2013
Last verified: December 2012
  Purpose
Platelets are blood cells that are important in coagulation of the blood. These cells have recently been shown to play a role in a number of other biologic processes, for example inflammation. In this study the investigators will determine the extent of platelet activation in people suffering from common chronic skin inflammation-urticaria and allergic dermatitis.

Condition Intervention
Urticaria
Atopic Dermatitis
Procedure: Blood sampling

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective

Resource links provided by NLM:


Further study details as provided by Meir Medical Center:

Primary Outcome Measures:
  • Platelet activation [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Platelet function will be assessed at enrollment


Secondary Outcome Measures:
  • Mean platelet volume [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Mean platelet volume will be assessed at enrollment


Estimated Enrollment: 80
Study Start Date: February 2013
Estimated Study Completion Date: October 2013
Estimated Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Skin disease
Patients with urticaria or atopic dermatitis
Procedure: Blood sampling
Blood sampling
Control
Healthy volunteers
Procedure: Blood sampling
Blood sampling

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Hospital clinic
Criteria

Inclusion Criteria: Urticaria or atopic dermatitis -

Exclusion Criteria:Lack of informed consent

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01759693

Locations
Israel
Meir Medical Center
Kfar Saba, Israel, 44281
Sponsors and Collaborators
Meir Medical Center
  More Information

Responsible Party: Meir Medical Center
ClinicalTrials.gov Identifier: NCT01759693     History of Changes
Other Study ID Numbers: 0113  MMC 0113 
Study First Received: December 28, 2012
Last Updated: January 2, 2013
Health Authority: Israel: Ethics Commission

Keywords provided by Meir Medical Center:
Platelet activation

Additional relevant MeSH terms:
Dermatitis
Dermatitis, Atopic
Eczema
Urticaria
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Skin Diseases, Vascular

ClinicalTrials.gov processed this record on December 07, 2016